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Abstract The prevalence of chronic kidney disease,
currently estimated to vary between 8 and 12 % in the
general population, is steadily rising due to aging and to the
ongoing epidemic of hypertension and type 2 diabetes.
Even in its early stages, chronic kidney disease entails a
greater risk for cardiovascular mortality, and its prevention
and treatment is rapidly becoming a key medical issue for
many health care systems worldwide. Adequate blood
pressure control and reduction of urine protein excretion,
preferably obtained by the use of renin-angiotensin-aldos-
terone system inhibitors, have traditionally been considered
the mainstay of therapeutic strategies in patients with renal
disease. Given the pivotal role of renin-angiotensin-aldos-
terone system activity in the pathogenesis and progression
of renal and cardiovascular damage, a more profound
inhibition of the system, either by the use of multiple
agents or by a single agent at high dosage has recently been
advocated, especially in the presence of proteinuria. Recent
trials, however have failed to confirm the usefulness of this
therapeutic approach, at least in unselected patients. This
article will critically review the current literature and will
discuss the clinical implications of targeting the renin-
angiotensin-aldosterone system in order to provide the
greatest renal protection.
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1 Introduction
Chronic kidney disease (CKD) is currently estimated to
affect between 8 and 12 % of the general population, and
its prevalence may be as high as 20–30 % in subgroups at
increased risk such as patients with diabetes, hypertension
and the elderly [1–3]. The economic impact of renal dis-
eases is steadily growing worldwide and its prevention and
treatment is becoming a priority for many public health
systems. In its early stages, besides the obvious risk of
progressing to end stage renal disease (ESRD) and the need
for renal replacement therapy, renal damage represents a
formidable multiplier of global cardiovascular (CV) risk
[4–6]. In fact, the presence of increased albuminuria or a
mild reduction in glomerular filtration rate, albeit typically
asymptomatic and often overlooked, entails a manifold
higher risk of unfavorable CV events [7]. CKD, especially
in the presence of significant proteinuria, typically remains
a progressive condition and since the decline in renal
function is paralleled by further increase in the burden of
risk, many patients actually die from CV complications
well before reaching ESRD [8, 9]. Although optimal
treatment for CKD has not yet been established, current
therapeutic strategies aim at correcting and optimizing
traditional and kidney specific CV risk factors. In this
respect, high blood pressure may well be regarded as a
special condition since it is known to be both a cause and a
consequence of renal damage [10]. Effective antihyper-
tensive treatment has clearly been shown to attenuate the
worsening of renal function and to reduce proteinuria [11].
While optimal blood pressure levels are still a matter of
debate and may vary on the basis of clinical conditions
such as the presence of diabetes and/or the degree of pro-
teinuria, there is consensus that maximizing the reduction
of urinary protein excretion is associated with better renal
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outcome, regardless of blood pressure changes and may
represent an intermediate target of treatment. International
guidelines unanimously recommend the use of renin-
angiotensin-aldosterone system (RAAS) inhibitors as the
pharmacological agent of choice to treat hypertension and
provide renal protection in CKD patients [12, 13]. The well
established pathogenetic role of the RAAS in promoting
and sustaining renal damage, both at experimental and
clinical levels, has led researchers to test the hypothesis
that a more profound inhibition of the system, achieved
through the concomitant use of multiple agents or through
the supramaximal dosage of a single agent may confer
additional therapeutic benefits. Recent clinical trials how-
ever do not seem to confirm this somewhat oversimplified
therapeutic scenario and once more emphasize the need for
a careful and individualized approach to antihypertensive
treatment in the renal patient [14, 15]. This article will
briefly review the recent literature on the pros and cons of
the use of RAAS-inhibitors and provide a practical algo-
rithm to optimize antihypertensive treatment in patients
with CKD.
2 Blood Pressure Lowering Reduces Proteinuria
and Conveys Renal and CV Protection
The magnitude of systolic blood pressure reduction as well
as the degree of proteinuria reduction has been related to
renal outcome in patients with non diabetic CKD, with
greater renal protection being obtained when these two
variables are lowered to a range of 110–130 mmHg and
below 1.5 g/day, respectively [16–18]. Furthermore, results
of the RENAAL and IDNT trials [19] indicate that residual
blood pressure and urine protein excretion levels, i.e. those
that can be achieved under optimal antihypertensive
treatment, are far more important for long term renal pro-
tection as compared to baseline values. Specifically, the
prognostic power of residual proteinuria seems to outweigh
that of blood pressure since a graded relationship between
the degree of proteinuria and the risk of reaching ESRD
was observed for each systolic blood pressure strata [20].
Furthermore, better long-term renal survival in patients
with overt proteinuria assigned to more intensive blood
pressure reduction was confirmed by recently published
data from the AASK study [21]. A similar relationship
between albuminuria and renal outcome has been shown to
apply also to earlier stages of the disease as indicated by an
association of albuminuria reduction with better preserva-
tion of GFR in the STENO-2 study carried out on patients
with type 2 diabetes [22]. Based on these data, international
guidelines have rather unanimously recommended blood
pressure values \130/80 mmHg (with some indicating
even lower values, i.e. \125/75 mmHg when proteinuria
exceeds 1 g/die) [23]. Recently, however, the wisdom and
evidence in favor of such a strict, often difficult to achieve
blood pressure target has been disputed since the untoward,
paradoxical increase in mortality (so called J curve phe-
nomenon) observed with progressively lower blood pres-
sure regimens has been confirmed in several trials,
especially in diabetics and coronary artery disease sub-
groups. Thus, it appears that while preservation of kidney
function may well be better obtained by maximal blood
pressure reduction, especially in the presence of protein-
uria, an overly ambitious target may not always be rec-
ommended in the overall interest of at least some CKD
patients, as global risk profile and the need to optimize
cerebrovascular and cardiac protection must be taken into
account as well [24].
3 RAAS Inhibitors: Renal Protection Beyond Blood
Pressure Reduction?
Extensive experimental and clinical evidence, accrued over
more than three decades, document the deleterious effects
of increased RAAS activity at the vascular and tissue level,
especially within the kidney [25]. An excess of angiotensin
II increases intraglomerular pressure by preferentially
constricting the efferent arterioles, thus promoting glo-
merular hypertension and protein trafficking through the
glomerular basal membrane [26, 27]. Furthermore, angio-
tensin II stimulates aldosterone production and triggers the
activation of a cascade of profibrotic cytokines whose
activation ultimately leads to cellular glomerular sclerosis
and tubule-interstitial fibrosis [28, 29]. Given these path-
ophysiological premises it is certainly not surprising that
antihypertensive agents which specifically inhibit RAAS
activity at various levels may exert antiproteinuric and
renoprotective effects even beyond their systemic hemo-
dynamic effect on blood pressure. Clinical confirmation of
this hypothesis was first provided in the early nineties by
the Collaborative Study Group Trial, whose results docu-
mented how the ACE-Inhibitor captopril afforded greater
proteinuria reduction and better renal survival as compared
to placebo in type 1 diabetic patients with overt renal
disease. Blood pressure reduction however was slightly but
significantly lower in the captopril arm, making it harder to
quantify precisely how much of the observed renal pro-
tection was specifically attributable to the drug’s mecha-
nism of action [30]. Greater renal protection as compared
to placebo was later reported with other ACE-Inhibitors
(ACE-I), namely ramipril and benazepril, in the REIN
study [31] and in the AIPRI study [32], both conducted on
non diabetic patients with proteinuric kidney diseases.
At the beginning of this century, the then new class of
angiotensin II type I receptor blockers (ARBs) was tested
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(again vs placebo) on the subgroup of patients that were
rapidly becoming the most prevalent in renal practice
everywhere, i.e. those with type 2 diabetes. In two similar
landmark trials [33, 34], losartan and irbesartan, given on
top of standard antihypertensive therapy, proved superior
to placebo in reducing proteinuria and the rate of renal
function loss over time, despite similar blood pressure
reduction. Although only a few clinical trials have formally
tested a head to head comparison between ACE-Is and
ARBs, based on the results of several small studies and one
reasonably large trial (comparing telmisartan and enalapril
in patients with type 2 diabetes and incipient renal disease)
[35], ACE-Is and ARBs have traditionally been assumed to
provide comparable renal protection, in the context of
undisputed superior tolerability of the latter. More recently,
a large trial [14], albeit not specifically carried out on renal
patients, reported similar renal protection with ramipril and
telmisartan in high risk patients. Despite minimal blood
pressure differences between treatment arms, which
required statistical adjustment, several [17, 18] but not all
meta-analyses [36] have sided with the notion of a certain
degree of additional, blood pressure independent renal
protective effect with ACE-I or ARBs. Guidelines have so
far acknowledged these results indicating ARBs as the
preferred choice in type 2 DM patients, and ACE-I for non
diabetic renal patients.
4 Optimizing RAAS Inhibition in Clinical Practice:
The Need for Limitation
After the initial enthusiasm over the results of trials con-
ducted with ACE-Is and ARBs, investigators realized that in
the presence of proteinuria, a disappointingly large fraction
of CKD patients, with or without diabetes, tend to progress
toward ESRD over a few years, despite optimal antihyper-
tensive treatment and RAAS-inhibition. In the meantime,
new experimental data uncovered several biochemical
mechanisms, such as non ACE-dependent Angiotensin II
formation pathways [37] or counter-regulatory supramaxi-
mal Angiotensin II production in the presence of ATI1 type I
receptor blockade [38, 39], the so called aldosterone escape
phenomenon, which provided the basis for hypothesizing an
incomplete blockade of the RAAS both under ACE-I or ARB
treatment. This led investigators to search for and test new
pharmacologic strategies to obtain more profound and
complete inhibition of the RAAS in order to achieve greater
renal protection (Table 1).
4.1 Dual RAAS Inhibition
Preliminary results of several small studies and three meta-
analyses [40–42] suggest that greater reduction of
proteinuria could be obtained by combining treatment with
an ACE-I and an ARB. One small study conducted on
patients with type 1 diabetes, with a triple cross over design
in 20 diabetic patients with overt proteinuria demonstrated
that high dose losartan or its association with lisinopril
(both at recommended doses) were superior to recom-
mended doses of losartan in reducing proteinuria [43].
These data contributed to raising expectations that dual
RAAS blockade could translate into long term reduction of
hard renal endpoints. However, following formal retraction
of the COOPERATE study [44, 45] and subsequently, after
publication of the much awaited renal data from ON-
TARGET [46], it appeared that the risk/benefit ratio of
RAAS combination therapy needed to be carefully recon-
sidered. While it has been pointed out that the ONTAR-
GET study included only a relatively small number of
CKD patients for its results to be applicable to the popu-
lation of renal patients at large, especially those with overt
proteinuria, this trial clearly showed that little o no CV
benefit can be gained by combining ramipril and telmi-
sartan in high risk patients. On the other hand, data show
there is a price to pay with this therapeutic combination in
terms of untoward effects, mainly hyperkalemia, hypoten-
sion and acute worsening of renal function, especially in
the subgroup with impaired renal function.
The development of aliskiren [47] the first direct renin
inhibitor (DRI), acting upstream of the enzymatic cascade
and providing more profound inhibition as well as greater
blood pressure lowering as compared to other agents,
allowed to test the usefulness of higher degrees of RAAS
suppression in the clinical setting. The AVOID study [48],
conducted on 600 hypertensive patients with type 2 dia-
betes and overt renal disease, showed additional antipro-
teinuric action and stable renal function when aliskiren was
given on top of losartan over a 6-month period, despite non
significant changes in blood pressure.
More recently, however the strategy of combining ali-
skiren with an ACE-I or an ARB in diabetic patients at high
cardiorenal risk was shown to entail potentially unfavor-
able effects. The ALTITUDE study, which was conducted
on 8,500 patients, had to be prematurely stopped due to
what turned out to be a lack of benefit, possibly associated
with a greater risk of complications [15]. Thus, it appears
that the risk-benefit ratio of pharmacological inhibition of
the RAAS may vary along the renal continuum and
seemingly paradoxical effects may be had when inhibition
becomes too profound or the clinical setting becomes
critical. While it is unlikely that dual RAAS inhibition does
any good to cardiovascular health, further studies are cer-
tainly needed before it can be concluded that it is detri-
mental to CKD patients, and some ongoing trials may
provide the much needed information. The VA NEPH-
RON-D trial will investigate the effect of combining





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































278 F. Viazzi et al.
losartan and lisinopril as compared to losartan alone in
patients with diabetes and overt proteinuria [49]. Further-
more, the LIRICO [50] and VALID [51] studies will again
evaluate dual therapy with either an ACE-I or an ARB in
patients with micro-macroalbuminuria and in those with
type 2 diabetes and overt nephropathy, respectively.
4.2 Single Agent High Dose RAAS Inhibition
Based on experimental studies indicating different degrees
of RAAS activity and drug effectiveness at the circulating
and tissue level [52–54], with the latter possibly more
accurately reflecting the development of organ damage in
the long term, it has been proposed that supra pharmaco-
logical doses of RAAS-inhibiting drugs might provide
greater renal benefit. Indeed, a few short-term studies have
documented dose-dependent reductions of proteinuria,
even regardless of hemodynamic changes [55–58]. Two
studies have investigated this possibility under chronic
conditions over the medium-long term. In the DROP study
[57], treatment of patients with type 2 diabetes and albu-
minuria with increasingly high doses of valsartan (up to
640 mg/day) were associated with a significantly greater
reduction in proteinuria and marginally lower blood pres-
sure. Along the same lines, in the SMART study [58], 269
non diabetic CKD patients with clinical proteinuria were
treated with candesartan up to 128 mg/day. While supra-
maximal doses did not seem to affect blood pressure val-
ues, urinary loss of protein was markedly reduced in a dose
dependent fashion. Finally, in the ROAD study [59] up-
titration of a single agent (benazepril or losartan) was
compared to standard dose in 360 non diabetic patients
with overt proteinuria over a three year follow-up period.
Again, high dose treatment with each agent was associated
with a greater antiproteinuric effect as compared to stan-
dard dose despite similar blood pressure reduction.
Undoubtedly, high dose monotherapy with ACE-I or ARB
appears to be a promising way to increase renal protection
in CKD patients and one which certainly warrants a more
in-depth evaluation by means of large well designed
studies in the future.
4.3 Aldosterone Receptor Antagonists
Several relatively small and short term studies have shown
that both spironolactone and eplerenone can produce fur-
ther reductions in albuminuria/proteinuria when added to
optimal treatment with an ACE-I or an ARB [60]. These
favorable results are corroborated by the results of at least
two meta-analyses [61, 62]. However, no long term effect
on renal function or survival has been documented, while
treatment is associated with a greater risk of potentially
dangerous untoward effects such as hyperkalemia,
particularly when eGFR is below 30 ml/min. In one study,
the addition of spironolactone 25 mg on top of high dose
lisinopril (i.e., 80 mg) was associated with further pro-
teinuria reduction regardless of blood pressure changes
[63]. Thus, notwithstanding encouraging preliminary evi-
dence, the routine use of an aldosterone receptor antagonist
(ARA) in association with an ACE or an ARB appears to
be premature and warrants further study.
5 What Role Could There Be for RAAS Inhibition
in the Prevention of Renal Damage?
The high CV and renal residual risk observed in patients
with overt CKD despite multifactorial intensive treatment
has prompted many to advocate prevention of renal dam-
age in the subgroups of patients at risk as a way to more
effectively fight the current epidemic of ESRD and asso-
ciated CV diseases. Again, even in the field of primary
prevention it has sometimes been difficult to distinguish the
effect of blood pressure lowering from that of RAAS
inhibition per se.
The BENEDICT study, carried out on patients with type
2 diabetes and hypertension, investigated the effectiveness
of the ACE-inhibitor trandolapril as compared to the non-
dihydropyridine calcium channel blocker verapamil given
alone or in combination, over a mean 3.6 year follow-up
period [64]. Treatment with trandolapril was associated
with a significantly lower incidence of microalbuminuria,
regardless of blood pressure values [65]. In the ADVANCE
trial, the combination of perindopril-indapamide proved
superior to placebo in preventing or delaying the onset of
microalbuminuria, although lower blood pressure values
were achieved in the active treatment arm [66]. Moreover,
in the DIRECT study, a large trial carried out on mostly
normotensive patients with type 1 and 2 diabetes, Cande-
sartan did not produce any valuable effect in preventing the
onset of albuminuria [67]. In another study, carried out on a
smaller number of patients with type 1 diabetes, neither
enalapril nor losartan showed any difference as compared
to placebo in preventing microalbuminuria over a 5 year
follow-up [68].
Finally, in the ROADMAP study, treatment with olme-
sartan was more effective than placebo in delaying the onset
of microalbuminuria in a large cohort of type 2 diabetics, but
again in the context of a slightly greater blood pressure
lowering effect as compared to placebo [69].
Taken together, these data suggest a mildly favorable
role for RAAS inhibitors in the prevention of renal damage
in patients with diabetes, especially in the context of
hypertension. This renal protective effect however, seems
at least in part due to the blood pressure lowering effect of
these agents.
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6 Conclusions
Achieving optimal blood pressure values through effective
pharmacological treatment is associated with a reduction in
proteinuria and a slower rate of renal deterioration over
time in patients with CKD. RAAS-Is represent the anti-
hypertensive drugs of choice and have been shown to
provide greater antiproteinuric effects at comparable blood
pressure regimens. Although only a few trials have directly
compared ACE-Is to ARBs, these two classes of antihy-
pertensives appear to have similar renal protective effec-
tiveness. The latter however, are characterized by
undisputed greater tolerability. Dual RAAS inhibition with
an ACE-I/ARB combination does not provide additional
CV benefits and might have serious side effects in the renal
patient. Whether these risks are worth taking in selected
cases, and if the slightly greater proteinuria reduction
reported with this combination will actually translate into
long term benefits on hard renal end point remains to be
seen. There are currently insufficient data to recommend
other RAAS combinations (with ARA or DRI) and high
dose monotherapy with ACE-I or ARB in order to achieve
greater renal protection. This is certainly an area that
warrants further clinical investigation.
In the presence of CKD, achieving blood pressure tar-
gets almost invariably requires the association of several
drugs [70], not rarely three or more. The type and dose or
combination of diuretic(s) is often a key factor for thera-
peutic success [71]. Whenever a two-drug combination is
sufficient to reach the desired blood pressure target, and in
the absence of other compelling indication to the use of
specific drug classes, RAAS-I and CCB can successfully be
used as initial treatment [72]. Finally, clinicians should
always be mindful that CKD requires all antihypertensive
regimens to be tailored to each specific clinical situation
and within the greater context of a multifactorial strategy
which must include a healthy lifestyle and dietary habits. In
particular, a decrease in sodium and phosphorus intake, and
a combination of antiplatelet, lipid lowering drugs and
optimal gluco-metabolic control as needed.
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